Heart-type fatty acid binding protein is related to severity and established cardiac biomarkers of heart failure.

Damien Gruson,Michel F Rousseau,Christina Adamantidou,Sylvie A Ahn

doi:10.1515/almed-2021-0035

Abstract

To determine concentrations of heart-type fatty acid-binding protein (HFABP) in patients with heart failure with reduced ejection fraction (HFrEF) and its potential value for prognostic assessment. Circulating levels of HFABP were measured with an automated chemiluminescent immunoassay in 25 healthy volunteers and 60 HFrEF patients. Concentrations of HFABP were significantly increased in heart failure patients in comparison to healthy volunteers. HFABP levels were significantly correlated to New York Heart Association classes and to established biomarkers of cardiac dysfunction and remodeling (amino-terminal pro-B-type natriuretic peptide [NT-proBNP], fibroblast growth factor 23, and galectin-3). HFABP concentrations were also predictive of cardiovascular (CV) death and combination with NT-proBNP might be synergistic for risk assessment. HFABP levels are increased in HFrEF patients, related to adverse CV outcomes, and might assist physicians for patient's management.

Highlights

Heart failure (HF) is affecting millions of people over the world and the disease is associated with a bad prognosis [1, 2]
Significant correlations were observed between heart-type fatty acid-binding protein (HFABP) levels, NT-proBNP, troponin I, galectin-3, and fibroblast growth factor 23 (FGF-23) (Table 1)
Our results showed that the rise of HFABP levels was related to the severity of HF, to established biomarkers of adverse cardiac remodeling, and to long-term CV death

Summary

Introduction

Heart failure (HF) is affecting millions of people over the world and the disease is associated with a bad prognosis [1, 2]. Novel biomarkers from different pathophysiological pathways might improve the risk stratification, outcome management, and the treatment selection of HF patients [1, 5, 6]. To this end, the added value of biomarkers related to cardiac remodeling and fibrosis, such as soluble ST2, galectin-3, or fibroblast growth factor 23 (FGF-23), as well as of biomarkers of myocardial necrosis like troponin has been investigated [7, 8]. The small cytoplasmic heart-type fatty acid-binding protein (HFABP) has been studied in a variety of disease entities and related to early detection of ischemia useful for early diagnosis of acute myocardial infarction [9, 10]. The increase in HFABP has been related to HF and its measurement might provide additional information for the risk stratification of HF patients [9, 10]

Objectives

Methods

Results

Conclusion